{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:30Z","timestamp":1787647110365,"version":"build-2736575974"},"reference-count":75,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Secretaria de Ciencia, Humanidades, Tecnologia e Inovacion","award":["811004"],"award-info":[{"award-number":["811004"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Piperacillin-tazobactam is widely used off-label in neonates for the empirical treatment of severe infections, resulting in diverse dosing regimens across clinical settings. This variability, combined with high interindividual differences in renal maturation that impact drug disposition, complicates standardized dosing and emphasizes the need for individualized, evidence-based strategies. This study aimed to develop and evaluate a population pharmacokinetic model of piperacillin in neonates to support optimized initial dosing recommendations. Neonatal patients (postnatal age \u226428 days) admitted to an intensive care unit who received piperacillin-tazobactam (8:1 ratio) at Neofax-recommended doses were included. Plasma concentrations were measured using an ultra-high-performance liquid chromatography with tandem mass spectrometry method. Population pharmacokinetic analysis for piperacillin was performed using nonlinear mixed-effects modeling. A total of 65 blood samples were collected from 25 neonates, both preterm (56%) and full-term. Piperacillin pharmacokinetics was best described by a one-compartment model incorporating body weight-based allometric scaling, postmenstrual age, and serum creatinine as covariates influencing clearance. For a typical neonate in the study (1.76 kg), the estimated clearance was 0.748 L\/h (coefficient of variation, 38.3%), and the volume of distribution was 0.866 L (37.7%). Simulations indicated adequate probability of target attainment with current recommendations, but a high proportion of preterm neonates (&gt;75%) were at risk of overexposure (trough piperacillin plasma concentration &gt;50 mg\/L). Additional simulations supported individualized initial regimens based on renal maturation and suggested that extended infusions (1\u22124 h) may improve target attainment for stricter targets and less-susceptible pathogens. This study provides a validated pharmacokinetic model for piperacillin in neonates with severe infections, offering a framework to optimize empiric dosing based on renal function and developmental stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.00998-25","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:06:21Z","timestamp":1764068781000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Population pharmacokinetics and dose optimization of piperacillin-tazobactam in premature and term neonates with severe infections"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2014-4197","authenticated-orcid":true,"given":"Frida S.","family":"Boer-P\u00e9rez","sequence":"first","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-6577","authenticated-orcid":true,"given":"Victoria","family":"Lima-Rogel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01m7mrx20","id-type":"ROR","asserted-by":"publisher"}],"name":"Neonatal Intensive Care Unit, Hospital Central \u201cDr. Ignacio Morones Prieto\u201d","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-3745","authenticated-orcid":true,"given":"Silvia","family":"Romano-Moreno","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-5687","authenticated-orcid":true,"given":"Ana R.","family":"Mej\u00eda-Elizondo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01m7mrx20","id-type":"ROR","asserted-by":"publisher"}],"name":"Neonatal Intensive Care Unit, Hospital Central \u201cDr. Ignacio Morones Prieto\u201d","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3962-8474","authenticated-orcid":true,"given":"Susanna E.","family":"Medell\u00edn-Garibay","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-4731","authenticated-orcid":true,"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/051mda743","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit of Innovative Treatments, Hospital de Pediatria JP Garrahan","place":["Buenos Aires, Argentina"]},{"id":[{"id":"https:\/\/ror.org\/011fq2d43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Council of Scientific and Technical Research (CONICET)","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-6742","authenticated-orcid":true,"given":"Daniel E.","family":"Noyola-Cherpitel","sequence":"additional","affiliation":[{"name":"Microbiology Department, Facultad de Medicina, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8403-0287","authenticated-orcid":true,"given":"Ana S.","family":"Rodr\u00edguez-B\u00e1ez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/041nas322","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-5208","authenticated-orcid":true,"given":"Cristian J.","family":"Rodr\u00edguez-Pinal","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-8184","authenticated-orcid":true,"given":"Rosa del C.","family":"Mil\u00e1n-Segovia","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Qu\u00edmicas, Universidad Aut\u00f3noma de San Luis Potos\u00ed","place":["San Luis Potos\u00ed, Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.894005"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semperi.2020.151322"},{"key":"e_1_3_5_4_2","unstructured":"World Health Organization. 2025. Global report on the epidemiology and burden of sepsis: current evidence identifying gaps and future directions. Geneva. Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/334216\/9789240010789-eng.pdf"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000315"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.05.048"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-022-04502-8"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13030220"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2024.10.003"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.2.166"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540500372879"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425250802614688"},{"key":"e_1_3_5_14_2","unstructured":"Food and Drug Administration (FDA). 2022. Prescribing information: ZOZYN (piperacillin and Tazobactam) for injection for intravenous use. Philadelphia. Available from: www.fda.gov\/medwatch"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30365-5"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.22.288623"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0732-y"},{"key":"e_1_3_5_18_2","unstructured":"Young T MangumB. 2024. Neofax by micromedex. Greenwood Village CO: Truven Health Analytics. Available from: https:\/\/www.micromedexsolutions.com"},{"key":"e_1_3_5_19_2","volume-title":"The Harriet Lane handbook: a manual for pediatric house officers","author":"Anderson C","year":"2023","unstructured":"Anderson C, Kapoor S, Mark T, Bennett J. 2023. Edited by Kliegman R and Geme J. The Harriet Lane handbook: a manual for pediatric house officers. 23rd ed. Elsevier, Philadelphia.","edition":"23"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181b12484"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002039"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2024.10.009"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.9.1320"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2385403"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clp.2024.10.005"},{"key":"e_1_3_5_26_2","unstructured":"U.S. Food and Drug Administration. 2022. FDA rationale for piperacillin-tazobactam breakpoints for Enterobacterales. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/fda-rationale-piperacillin-tazobactam-breakpoints-enterobacterales. Retrieved 14 Jan 2025."},{"key":"e_1_3_5_27_2","unstructured":"U.S. Food and Drug Administration. 2024. FDA rationale for breakpoints recognition decision: piperacillin-tazobactam and Pseudomonas aeruginosa. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/fda-rationale-breakpoints-recognition-decision-piperacillin-tazobactam-and-pseudomonas-aeruginosa. Retrieved 14 Jan 2025."},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182587665"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02139-13"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121747"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(03)00030-9"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1284"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12070685"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.524"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0997-5"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15058"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2131-0"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001610"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1413-4"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01460-6"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00366"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1208\/ps020103"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad196"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13160"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11091142"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_a.39"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01745246"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2817"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1172"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3423"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.777854"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02089-15"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu027"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac416"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01230-w"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.11.006"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-306213"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365510050184949"},{"key":"e_1_3_5_60_2","unstructured":"United States Food and Drug Administration (FDA). 2022. General clinical pharmacology considerations for neonatal studies for drugs and biological products: guidance for industry. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance. Retrieved 13 May 2025."},{"key":"e_1_3_5_61_2","unstructured":"European Medicines Agency. 2009. Guideline on the investigation of medicinal products in the term and preterm neonate. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-medicinal-products-term-preterm-neonate-first-version_en.pdf"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171717"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(84)80479-5"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-024-00906-3"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-003367"},{"key":"e_1_3_5_66_2","unstructured":"U.S. Food and Drug Administration (FDA). 2018. Bioanalytical method validation guidance for industry. Available from: https:\/\/www.fda.gov\/media\/70858\/download"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0189-x"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx093"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2007.12.002"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-13-59"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.103.4.e49"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00439.2013"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-22.3.212"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00998-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00998-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:01:27Z","timestamp":1767794487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00998-25"}},"subtitle":[],"editor":[{"given":"James E.","family":"Leggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"alternative-id":["10.1128\/aac.00998-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.00998-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2025-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00998-25"}}